Research programme: cancer therapeutics - CK Life Sciences
Alternative Names: CKBP 002; CKBP 004Latest Information Update: 04 Nov 2017
At a glance
- Originator CK Life Sciences
- Developer Cedars-Sinai Health System; CK Life Sciences; University of California at Los Angeles
- Class
- Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors; Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Hong Kong
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 06 Jul 2011 Preclinical development is ongoing in Hong Kong and USA